Alzheimer’s Disease Drug Developed at Roskamp Institute Approved for Key Clinical Trial Funding in Europe

Published: May 25, 2011

An international research consortium led by Trinity College Dublin (Ireland) today announced the selection for funding of a large-scale European clinical trial of Nilvadipine, an Alzheimer’s disease drug developed at the Roskamp Institute in Sarasota. More than 500 Alzheimer’s patients will participate in the multicenter Phase III clinical trial designed to study the effectiveness of Nilvadipine.

Back to news